Insulin-like Growth Factor-1-and Interleukin-6-related Gene Variation and Risk of Multiple Myeloma

Washington University in St. Louis, San Luis, Missouri, United States
Cancer Epidemiology Biomarkers & Prevention (Impact Factor: 4.13). 01/2009; 18(1):282-8. DOI: 10.1158/1055-9965.EPI-08-0778
Source: PubMed


Insulin-like growth factor (IGF)-1 and interleukin (IL)-6 promote the proliferation and survival of multiple myeloma cells. Variation in genes related to IGF-1 and IL-6 signaling may influence susceptibility to multiple myeloma. To assess their etiologic role, we examined the association of 70 tagging single nucleotide polymorphisms (SNP) in seven IGF-1 and three IL-6 pathway genes with multiple myeloma risk in two prospective cohorts, the Nurses' Health Study and the Health Professionals Follow-up Study. Among the participants who provided DNA specimens, we identified 58 women and 24 men with multiple myeloma and matched two controls per case. We used multivariable logistic regression models to assess the association of the SNPs or tagged haplotypes with multiple myeloma risk. Several SNPs had suggestive associations with multiple myeloma based on large odds ratios (OR), although the corresponding omnibus P values were not more than nominally significant (i.e., at P < 0.05). These SNPs included rs1801278 in the gene encoding insulin receptor substrate-1 [IRS1; C/T versus C/C genotypes; OR, 4.3; 95% confidence interval (CI), 1.5-12.1] and three IL-6 receptor SNPs: rs6684439 (T/T versus C/C; OR, 2.9; 95% CI, 1.2-7.0), rs7529229 (C/C versus T/T; OR, 2.5; 95% CI, 1.1-6.0), and rs8192284 (C/C versus A/A; OR, 2.5, 95% CI, 1.1-6.0). Additional SNPs in genes encoding IGF-1, IGF binding protein-2, IRS2, and gp130 also showed suggestive associations with multiple myeloma risk. We conducted a large number of statistical tests, and the findings may be due to chance. Nonetheless, the data are consistent with the hypothesis that IGF-1- and IL-6-related gene variation influences susceptibility to multiple myeloma and warrant confirmation in larger populations.

Download full-text


Available from: Graham A Colditz, Oct 04, 2015
19 Reads
  • Source
    • "The current analysis includes women with available DNA who were controls from 7 nested case–control studies of IGF-1 and IGBFP-3 SNPs and risk of various chronic diseases, including benign breast disease [17], breast cancer [5], endometrial cancer [18], myeloma [19], and ovarian cancer [20] (N=4567). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Background Early life body size and circulating levels of IGF-1 and IGFBP-3 have been linked to increased risks of breast and other cancers, but it is unclear whether these exposures act through a common mechanism. Previous studies have examined the role of IGF-1 and IGFBP-3 genetic variation in relation to adult height and body size, but few studies have examined associations with birthweight and childhood size. Methods We examined whether htSNPs in IGF-1 and the IGFBP-1/IGFBP-3 gene region are associated with the self-reported outcomes of birthweight, body fatness at ages 5 and 10, and body mass index (BMI) at age 18 among healthy women from the Nurses’ Health Study (NHS) and NHSII. We used ordinal logistic regression to model odds ratios (ORs) and 95% confidence intervals (CI) of a one category increase for birthweight and somatotypes at ages 5 and 10. We used linear regression to model associations with BMI at age 18. Results Among 4567 healthy women in NHS and NHSII, we observed no association between common IGF-1 or IGFBP-1/IGFBP-3 SNPs and birthweight, body fatness at ages 5 and 10, or BMI at age 18. Conclusions Common IGF-1 and IGFBP-1/IGFBP-3 SNPs are not associated with body size in early life.
    BMC Public Health 08/2012; 12(1):659. DOI:10.1186/1471-2458-12-659 · 2.26 Impact Factor
  • Source
    • "Over the past few years, several studies have shown that inhibition of these signalling pathways by specific inhibitors or by blocking the activator of these pathways causes an inhibition of cell proliferation [31], [32]. The proliferation and the survival of MM cells are strongly dependent on the activation of signalization pathways by cytokines and growth factors [33], [34], [35]. Most of these cytokines and growth factors are secreted by the microenvironment, in particular the bone marrow stromal cells [36], [37]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Multiple myeloma (MM) is a B cell neoplasm characterized by bone marrow infiltration with malignant plasma cells. IGF-1 signalling has been explored as a therapeutic target in this disease. We analyzed the effect of the IKK2 inhibitor AS602868, in combination with a monoclonal antibody targeting IGF-1 receptor (anti-IGF-1R) in human MM cell lines. We found that anti-IGF-1R potentiated the apoptotic effect of AS602868 in LP1 and RPMI8226 MM cell lines which express high levels of IGF-1R. Anti-IGF-1R enhanced the inhibitory effect of AS602868 on NF-κB pathway signalling and potentiated the disruption of mitochondrial membrane potential caused by AS602868. These results support the role of IGF-1 signalling in MM and suggest that inhibition of this pathway could sensitize MM cells to NF-κB inhibitors.
    PLoS ONE 07/2011; 6(7):e22641. DOI:10.1371/journal.pone.0022641 · 3.23 Impact Factor
  • Source
    • "The Rotterdam Study found high levels of CRP to be associated with an increased risk of incident cancer with the strongest association for lung cancer (Siemes, Visser et al. 2006). IL-6 related gene variation was found to be associated with multiple myeloma in the Nurses' Health Study and the Health Professionals Follow-up Study (Birmann, Tamimi et al. 2009). "
    [Show abstract] [Hide abstract]
    ABSTRACT: To review findings from major epidemiologic studies regarding risk factors for and consequences of elevated markers of inflammation in older adults. Most large, current epidemiologic studies of older adults have measured serum interleukin-6 (IL-6), C-reactive protein (CRP) and tumor necrosis factor alpha (TNF-alpha) and some studies also include more extensive batteries of measures including soluble receptors. There are few defined risk factors for the modest elevations in inflammatory markers seen with aging. These include visceral adiposity, lower sex steroid hormones, smoking, depression and periodontal disease. Of the markers assessed, IL-6 is most robustly associated with incident disease, disability and mortality. Though correlated with age, the etiology of elevated inflammatory markers remains incompletely defined. Inflammation, especially IL-6 may be a common cause of multiple age-related diseases or a final common pathway by which disease leads to disability and adverse outcomes in older adults. Future research targeting inflammation should examine these pathways.
    Ageing research reviews 12/2010; 10(3):319-29. DOI:10.1016/j.arr.2010.11.002 · 4.94 Impact Factor
Show more